An escalating health emergency tests international cooperation and scientific readiness.
Kinshasa, Democratic Republic of the Congo.
The European Union is sending two epidemiologists to the Democratic Republic of the Congo as health authorities intensify their response to a major Ebola outbreak and begin clinical research involving an existing vaccine. The European Centre for Disease Prevention and Control (ECDC) announced the deployment on September 21, emphasizing the need to reinforce disease surveillance and outbreak management. More than 7,600 confirmed infections and 3,670 deaths have been reported, underscoring the scale of the emergency.
The outbreak is concentrated primarily in Ituri province, which accounts for nearly 80% of recorded infections. However, transmission across other affected areas has complicated efforts to contain the disease. Pamela Rendi-Wagner, director of the ECDC, said the additional specialists would strengthen surveillance and support the overall response in the outbreak’s epicenter.
European assistance began before the latest deployment. Since May, the ECDC has provided technical support to the Africa Centres for Disease Control and Prevention. In June, European specialists assessed airport exit-screening procedures in Congo and Uganda, while additional experts were deployed to South Sudan. These activities reflect the importance of regional surveillance when population movement crosses national borders.
The scientific response has entered a critical phase. The World Health Organization announced the beginning of a research vaccination program in Ituri using Ervebo, an Ebola vaccine already authorized against the Zaire virus. The current epidemic, however, is caused by the Bundibugyo virus, against which no vaccine or specific treatment has been approved.
A total of 70,000 Ervebo doses have been allocated to support the response and associated research. Of these, 20,000 are designated for a Phase III clinical trial investigating whether the vaccine can protect against Bundibugyo infection. The remaining 50,000 doses have been allocated for healthcare personnel and other frontline workers under the research-based response arrangements.
The distinction between an authorized vaccine and an experimentally evaluated application is essential. Ervebo has demonstrated strong effectiveness against the Zaire Ebola virus, but its ability to protect humans against Bundibugyo remains unknown. Preliminary laboratory and animal evidence suggests possible cross-protection, although those findings cannot establish clinical effectiveness in humans. The WHO therefore recommends its use against Bundibugyo only within research protocols.
Despite the seriousness of the outbreak, the ECDC assesses the risk of infection being imported into the European Union as very low. Isolated imported cases remain possible, but multiple independent introductions are considered unlikely. Ebola spreads primarily through direct contact with infected bodily fluids or materials contaminated by them, rather than through ordinary casual contact.
The emergency illustrates the relationship between immediate public health intervention and scientific uncertainty. Surveillance, clinical care and community engagement remain indispensable while researchers investigate whether an existing vaccine can provide protection against a different Ebola virus.
The outcome will influence not only the response in Congo but also international preparedness for future outbreaks involving viruses for which proven medical countermeasures remain unavailable.
Phoenix24: inteligencia para audiencias libres. / Phoenix24: intelligence for free audiences.